Prosecution Insights
Last updated: May 29, 2026

Aquestive Therapeutics, Inc.

7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
6
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
3
Medium (43%)
1
Easy (14%)
3
Unknown (43%)

Rejection Statute Mix

BucketCases
§103 only3 (43%)
§112 only1 (14%)
No statute on record3 (43%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LIPPERT, JOHN WILLIAM 1 55.7% +42.6%
KIM, DANIELLE A 1 37.2% +58.0%
SEAMAN, D MARGARET M 1 76.6% +8.0%
HUI, SAN MING R 1 59.0% +20.0%
ABUZEINEH, HANAN ISAM 1 56.9% +49.3%
YOUNG, MICAH PAUL 1 55.1% +30.1%
PHAN, DOAN THI-THUC 1 42.7% +49.8%

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
16143036 DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS PHAN, DOAN THI-THUC 99d overdue
17086409 PRODRUG COMPOSITIONS AND METHODS OF TREATMENT HUI, SAN MING R 86d overdue
16143678 PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION YOUNG, MICAH PAUL 86d overdue
17971282 PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY PROFILES LIPPERT, JOHN WILLIAM 24d overdue
17691107 DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES KIM, DANIELLE A 5d overdue
17031207 SUBLINGUAL AND BUCCAL FILM COMPOSITIONS ABUZEINEH, HANAN ISAM 15d

Top Art Units

Art UnitApps
1613 2
1615 1
1625 1
1627 1
1633 1
1618 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17971282 PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY PROFILES LIPPERT, JOHN WILLIAM 1615 §103 Non-Final OA 24d overdue Pending Oct 21, 2022
17691107 DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES KIM, DANIELLE A 1613 §103 Final Rejection 5d overdue Pending Mar 09, 2022
17576923 PRODRUG COMPOSITIONS AND METHODS OF TREATMENT SEAMAN, D MARGARET M 1625 §112 Non-Final OA 19d Pending Jan 15, 2022
17086409 PRODRUG COMPOSITIONS AND METHODS OF TREATMENT HUI, SAN MING R 1627 Other Non-Final OA 86d overdue Pending Nov 01, 2020
17031207 SUBLINGUAL AND BUCCAL FILM COMPOSITIONS ABUZEINEH, HANAN ISAM 1633 Other Non-Final OA 15d Pending Sep 24, 2020
16143678 PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION YOUNG, MICAH PAUL 1618 Other Non-Final OA 86d overdue Pending Sep 27, 2018
16143036 DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS PHAN, DOAN THI-THUC 1613 §103 Non-Final OA 99d overdue Pending Sep 26, 2018

Managing Aquestive Therapeutics, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month